HRP20211271T1 - Pripravci aripiprazolskog predlijeka - Google Patents

Pripravci aripiprazolskog predlijeka Download PDF

Info

Publication number
HRP20211271T1
HRP20211271T1 HRP20211271TT HRP20211271T HRP20211271T1 HR P20211271 T1 HRP20211271 T1 HR P20211271T1 HR P20211271T T HRP20211271T T HR P20211271TT HR P20211271 T HRP20211271 T HR P20211271T HR P20211271 T1 HRP20211271 T1 HR P20211271T1
Authority
HR
Croatia
Prior art keywords
aripiprazole prodrug
stabilizer
surface stabilizer
particles
composition
Prior art date
Application number
HRP20211271TT
Other languages
English (en)
Croatian (hr)
Inventor
Philip Cresswell
Magali Hickey
Elaine Liversidge
David Manser
Michael PALMIERI
Sara Montminy Paquette
Kristopher Perkin
Greg Smith
Brian STEINBERG
Ryan Turncliff
Tarek Zeidan
Ethan P. Cash
Marjie L. Hard
Original Assignee
Alkermes Pharma Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51352472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20211271(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Limited filed Critical Alkermes Pharma Ireland Limited
Publication of HRP20211271T1 publication Critical patent/HRP20211271T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20211271TT 2014-08-18 2015-08-17 Pripravci aripiprazolskog predlijeka HRP20211271T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462038665P 2014-08-18 2014-08-18
EP14181328 2014-08-18
EP19154013.7A EP3508196B1 (en) 2014-08-18 2015-08-17 Aripiprazole prodrug compositions

Publications (1)

Publication Number Publication Date
HRP20211271T1 true HRP20211271T1 (hr) 2022-01-07

Family

ID=51352472

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211271TT HRP20211271T1 (hr) 2014-08-18 2015-08-17 Pripravci aripiprazolskog predlijeka

Country Status (20)

Country Link
US (1) US12642798B2 (cg-RX-API-DMAC10.html)
EP (2) EP3508196B1 (cg-RX-API-DMAC10.html)
JP (1) JP6571166B2 (cg-RX-API-DMAC10.html)
CN (3) CN112494492B (cg-RX-API-DMAC10.html)
AU (1) AU2015306198B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017002926A2 (cg-RX-API-DMAC10.html)
CY (1) CY1124625T1 (cg-RX-API-DMAC10.html)
DK (1) DK3508196T3 (cg-RX-API-DMAC10.html)
ES (1) ES2884849T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20211271T1 (cg-RX-API-DMAC10.html)
HU (1) HUE055711T2 (cg-RX-API-DMAC10.html)
IL (2) IL292079B2 (cg-RX-API-DMAC10.html)
MX (1) MX371417B (cg-RX-API-DMAC10.html)
PL (2) PL3508196T3 (cg-RX-API-DMAC10.html)
PT (1) PT3508196T (cg-RX-API-DMAC10.html)
RS (2) RS58746B2 (cg-RX-API-DMAC10.html)
RU (1) RU2705376C2 (cg-RX-API-DMAC10.html)
SI (2) SI3508196T1 (cg-RX-API-DMAC10.html)
SM (2) SMT202100481T1 (cg-RX-API-DMAC10.html)
WO (1) WO2016026822A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
TR201905694T4 (tr) * 2014-08-18 2019-05-21 Alkermes Pharma Ireland Ltd Aripiprazol ön ilaç bileşimleri.
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
CA3014788A1 (en) 2016-02-17 2017-08-24 Alkermes Pharma Ireland Limited Compositions of multiple aripiprazole prodrugs
CN110025572A (zh) * 2018-01-11 2019-07-19 四川科伦药物研究院有限公司 月桂酰阿立哌唑混悬剂及其制备方法
AU2019230014B2 (en) * 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
WO2022260064A1 (ja) 2021-06-08 2022-12-15 中外製薬株式会社 ジヒドロピリダジン-3,5-ジオン誘導体を含有する製剤

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
ES2306452T3 (es) 1995-10-17 2008-11-01 Jagotec Ag Aporte de farmacos insolubles.
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル,リミティド 即時放出および徐放特性を組み合わせて有する組成物
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
DE10350717A1 (de) * 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
WO2007035348A2 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US20120238553A1 (en) 2009-01-27 2012-09-20 Neurosearch A/S Novel benzodioxolyl-oxadiazolyl-diazabicyclononane derivatives and their medical use
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ
PT2445502T (pt) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
CA3035442C (en) * 2009-06-25 2022-07-19 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
ES2972387T3 (es) * 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
CA2867121C (en) * 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
SMT202100481T1 (it) 2014-08-18 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni per profarmaci di aripiprazolo
SMT202100212T1 (it) 2014-08-25 2021-07-12 Alkermes Pharma Ireland Ltd Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia
CN105012236A (zh) 2015-08-10 2015-11-04 深圳市泛谷药业有限公司 一种长效非水载体注射液及其制备方法

Also Published As

Publication number Publication date
CA2957762A1 (en) 2016-02-25
RS58746B1 (sr) 2019-06-28
MX2017002029A (es) 2017-08-14
ES2884849T3 (es) 2021-12-13
RS62232B1 (sr) 2021-09-30
RU2705376C2 (ru) 2019-11-07
EP3182958B1 (en) 2019-02-27
CN112494492A (zh) 2021-03-16
AU2015306198B2 (en) 2021-02-25
RU2017108204A (ru) 2018-09-21
PL3508196T3 (pl) 2021-12-20
CN112494492B (zh) 2023-08-25
DK3508196T3 (da) 2021-08-16
IL292079B2 (en) 2024-07-01
NZ767204A (en) 2024-02-23
CY1124625T1 (el) 2022-07-22
EP3182958A1 (en) 2017-06-28
CN106794251B (zh) 2020-12-29
JP2017524021A (ja) 2017-08-24
PL3182958T5 (pl) 2022-09-12
RS58746B2 (sr) 2022-07-29
PT3508196T (pt) 2021-08-25
JP6571166B2 (ja) 2019-09-04
EP3508196A1 (en) 2019-07-10
SMT202100481T1 (it) 2021-09-14
SI3182958T1 (sl) 2019-05-31
CN106794251A (zh) 2017-05-31
IL292079B1 (en) 2024-03-01
EP3182958B2 (en) 2022-05-18
SI3182958T2 (sl) 2022-07-29
HUE055711T2 (hu) 2021-12-28
MX371417B (es) 2020-01-29
BR112017002926A2 (pt) 2017-12-12
PL3182958T3 (pl) 2019-07-31
US12642798B2 (en) 2026-06-02
AU2015306198A1 (en) 2017-03-02
NZ728914A (en) 2023-11-24
EP3508196B1 (en) 2021-07-14
RU2017108204A3 (cg-RX-API-DMAC10.html) 2019-04-04
WO2016026822A1 (en) 2016-02-25
SMT201900236T1 (it) 2019-07-11
IL292079A (en) 2022-06-01
IL250607A0 (en) 2017-04-30
SI3508196T1 (sl) 2021-12-31
CN112641785A (zh) 2021-04-13
IL250607B (en) 2022-05-01
US20220079939A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
Fabiańska et al. Biomarkers, aromatic hydrocarbons and polar compounds in the Neogene lignites and gangue sediments of the Konin and Turoszów Brown Coal Basins (Poland)
Singh Petrology and geochemistry of Abyssal Peridotites from the Manipur Ophiolite Complex, Indo-Myanmar Orogenic Belt, Northeast India: Implication for melt generation in mid-oceanic ridge environment
MX2017001812A (es) Composiciones de formulacion liquida, aparatos de administracion de medicamentos, y metodos de preparacion y uso de los mismos.
MX371417B (es) Composiciones de profarmacos de aripiprazol.
JP2016527665A5 (cg-RX-API-DMAC10.html)
CL2015002066A1 (es) Composiciones que incluye agentes para conferir carácter hidrofóbico y estabilizantes y métodos para elaborar y usar los mismos.
WO2015027054A3 (en) Telodendrimers and nanocarriers and methods of using same
BR112016006789A2 (pt) composição acrílica endurecível de múltiplas partes, uso de uma primeira parte sólida de polímero acrílico, e, métodos para produzir um cimento acrílico e para produzir uma composição acrílica endurecível de múltiplas partes
HRP20191366T4 (hr) Injekcijski pripravak
EA202090731A1 (ru) Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка
MX2015009926A (es) Silice funcionalizada con aglutinante de elastomero.
JP2017524021A5 (cg-RX-API-DMAC10.html)
NZ720512A (en) Multi-particulate drug delivery system
MY173159A (en) Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
BR112015029773A2 (pt) pós revestidos com aroma
JP2016135110A5 (cg-RX-API-DMAC10.html)
MY183106A (en) Fine dry particulate retinoid active agent compostions and topical formulations including the same
Lombardo Explicit surjectivity of Galois representations for abelian surfaces and GL2-varieties
AR112448A1 (es) Derivados de xantina sustituidos
WO2015007999A3 (fr) Farine de microalgues riches en lipides et procede de preparation
MX346407B (es) Composiciones cosmeticas de aceite-en-agua.
Guo et al. The effect of shipping stresses on vaccine re-dispersion time
MX2020001348A (es) Proceso para la disolución rápida de polvo que comprende polímero a base de acrilamida de bajo peso molecular.
RU2019134055A (ru) Композиции пролекарства арипипразола
MY186810A (en) Mixture of solvents for removing asphaltenes